These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16006772)

  • 41. Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer.
    Iwata T; Tanaka K; Inoue Y; Toiyama Y; Hiro J; Fujikawa H; Okugawa Y; Uchida K; Mohri Y; Kusunoki M
    J Surg Oncol; 2013 Feb; 107(2):160-6. PubMed ID: 22926691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of serum interleukin-17 levels in colorectal cancer patients.
    Karabulut S; Usul Afsar C; Karabulut M; Kilic L; Alis H; Kones O; Bilgin E; Faruk Aykan N
    J BUON; 2016; 21(5):1137-1145. PubMed ID: 27837615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients.
    Ito H; Miki C
    Scand J Gastroenterol; 1999 Nov; 34(11):1139-43. PubMed ID: 10582766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of the combined measurement of serum B7-H1 and interleukin-10 in colorectal cancer patients.
    Wang P; Li C; Ma X; Gai X
    Medicine (Baltimore); 2020 May; 99(18):e20044. PubMed ID: 32358386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer.
    Yeh KY; Li YY; Hsieh LL; Lu CH; Chou WC; Liaw CC; Tang RP; Liao SK
    Jpn J Clin Oncol; 2010 Jun; 40(6):580-7. PubMed ID: 20194250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Level of soluble tumor necrosis factor receptor type I in patients with systemic scleroderma].
    Alekperov RT; Timchenko AV; Samsonov MIu; Guseva NG; Nasonov EL
    Ter Arkh; 2004; 76(5):11-5. PubMed ID: 15230124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer.
    Kim YW; Kim SK; Kim CS; Kim IY; Cho MY; Kim NK
    Anticancer Res; 2014 Jul; 34(7):3481-7. PubMed ID: 24982357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case-control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer.
    Duvillard L; Ortega-Deballon P; Bourredjem A; Scherrer ML; Mantion G; Delhorme JB; Deguelte-Lardière S; Petit JM; Bonithon-Kopp C;
    BMC Cancer; 2014 Dec; 14():912. PubMed ID: 25472811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Granulocyte-colony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in colorectal cancer patients.
    Mroczko B; Szmitkowski M; Okulczyk B
    Clin Chem Lab Med; 2002 Apr; 40(4):351-5. PubMed ID: 12059074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble cytokine receptors sTNFR I and sTNFR II, receptor antagonist IL-1ra, and anti-inflammatory cytokines IL-10 and IL-13 in the pathogenesis of systemic inflammatory response syndrome in the course of burns in children.
    Sikora JP; Kuzański W; Andrzejewska E
    Med Sci Monit; 2009 Jan; 15(1):CR26-31. PubMed ID: 19114968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications.
    Nikiteas NI; Tzanakis N; Gazouli M; Rallis G; Daniilidis K; Theodoropoulos G; Kostakis A; Peros G
    World J Gastroenterol; 2005 Mar; 11(11):1639-43. PubMed ID: 15786541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.
    Takasugi K; Yamamura M; Iwahashi M; Otsuka F; Yamana J; Sunahori K; Kawashima M; Yamada M; Makino H
    Arthritis Res Ther; 2006; 8(4):R126. PubMed ID: 16859503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
    Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
    Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients.
    Jabłońska E; Pietruska Z
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):449-53. PubMed ID: 9437501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential of serum levels of soluble tumour necrosis factor receptor I as a biochemical marker in cervical cancer.
    Sheu BC; Lin HH; Chang DY; Ho HN; Huang SC
    Br J Obstet Gynaecol; 1997 Nov; 104(11):1314-9. PubMed ID: 9386035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytokines and heart rate variability in patients with chronic heart failure.
    Straburzyńska-Migaj E; Ochotny R; Wachowiak-Baszyńska A; Straburzyńska-Lupa A; Leśniewska K; Wiktorowicz K; Cieśliński A
    Kardiol Pol; 2005 Nov; 63(5):478-85; discussion 486-7. PubMed ID: 16362851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.
    Haack M; Hinze-Selch D; Fenzel T; Kraus T; Kühn M; Schuld A; Pollmächer T
    J Psychiatr Res; 1999; 33(5):407-18. PubMed ID: 10504009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
    Schmid I; Schmitt M; Streiter M; Meilbeck R; Haas RJ; Stachel DK
    Eur J Med Res; 2005 Nov; 10(11):457-61. PubMed ID: 16354598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.